Glenmark Pharmaceuticals announced the launch of Bumetanide injection, a diuretic used to treat fluid accumulation caused by congestive heart failure, liver or kidney disease, or other medical conditions. Bumetanide is the generic name for Validus Pharmaceuticals LLC’s Bumex injection (0.25 mg/mL).
Glenmark stated in its filing with the exchanges that it will offer Bumetanide injection USP in single-dose vials of 1 mg/4 mL (0.25 mg/mL) and multi-dose vials of 2.5 mg/10 mL (0.25 mg/mL).The company was pleased to bring to market a lower-cost alternative to the Bumex injection. According to IQVIA, a research firm, Bumex injection 0.25 mg/mL had annual sales of $16.5 million in the United States for the 12-month period ending November 2022.